Research Papers:

Development of a Taiwan cancer-related fatigue cognition questionnaire: reliability and validity

Shih-Chiung Lai, Wei-Chun Lin, Chien-Hsin Chen and Szu-Yuan Wu _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:28880-28887. https://doi.org/10.18632/oncotarget.16285

Metrics: PDF 1272 views  |   HTML 1567 views  |   ?  


Shih-Chiung Lai1,*,Wei-Chun Lin2,*, Chien-Hsin Chen3, Szu-Yuan Wu4,5,6,7

1Department of Exercise and Health Science, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan

2Department of Cancer Research Center, Wan Fang Hospital, Taipei Medical University, Taiwan

3Department of Colorectal Surgery, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan

4Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan

5Department of Radiation Oncology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan

6Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

7Department of Biotechnology, Hungkuang University, Taichung, Taiwan

*These authors contributed equally to this work and are joint first authors

Correspondence to:

Szu-Yuan Wu, email: szuyuanwu5399@gmail.com

Keywords: cancer-related fatigue questionnaire, reliability, validity

Received: October 17, 2016     Accepted: February 06, 2017     Published: March 16, 2017


Purpose: We prospectively designed a Taiwan cancer-related fatigue cognition questionnaire, version 1.0 (TCRFCQ-V1.0), for Taiwanese patients with cancer and investigated the reliability and validity of this questionnaire.

Results: The completion rate of the TCRFCQ-V1.0 was high (97% of the patients completed all items), and the rate of missing data was low (0.2%–1.1% for each item). Moreover, the Cronbach alpha value was 0.889. We eliminated 5 items because their respective Cronbach alpha values were higher than the total mean value of Cronbach’s alpha. Overall, the TCRFCQ-V1.0 had adequate Cronbach alpha coefficients (range, from 0.882 to 0.889). In addition, the results of Bartlett’s test were significant (chi-squared, 2390.11; p < 0.001), indicating the appropriateness of factor analysis. Sampling adequacy was confirmed by the Kaiser–Meyer–Olkin statistic of 0.868. Through exploratory factor analysis, we identified 6 factors with eigenvalues of > 1, and the scree plot indicated no flattening factors. Overall, 28 items achieved a factor loading of ≥ 0.55.

Materials and Methods: We enrolled patients with cancer who were aged > 18 years, had received a pathological diagnosis of cancer, and had undergone cancer treatments such as surgery, chemotherapy, radiotherapy, or concurrent chemoradiotherapy at a single institute in Taiwan. Of the identified 167 eligible patients, 161 (96.4%) were approached. Of these patients, 6 (7.2%) declined to participate and 155 (92.8%) were interviewed. The initial 43 items in the TCRFCQ-V1.0 were assessed for ceiling and floor effects.

Conclusions: The TCRFCQ-V1.0 is a reliable and valid instrument for measuring CRF cognition in Taiwanese patients with cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16285